Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors |
| |
| Institution: | 1. Small Molecule Research, Pharma Research & Early Development, pRED, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110, United States;2. Roche Palo Alto, 3401 Hillview Ave, Palo Alto, CA 94304, United States;1. Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26?1, Muraoka?Higashi 2?chome, Fujisawa, Kanagawa 251?8555, Japan;2. Takeda California, Inc., 10410 Science Center Drive, San Diego, CA 92121, United States;1. Synthex Technologies Sp. z o.o., Gagarina 7/134B, 87-100 Toruń, Poland;2. Nicolaus Copernicus University, Faculty of Chemistry, Gagarina 7, 87-100 Toruń, Poland |
| |
| Abstract: | A new class of Janus kinase (JAK) inhibitors was discovered using a rationally designed pyrrolo1,2-b]pyridazine-3-carboxamide scaffold. Preliminary studies identified (R)-(2,2-dimethylcyclopentyl)amine as a preferred C4 substituent on the pyrrolopyridazine core (3b). Incorporation of amino group to 3-position of the cyclopentane ring resulted in a series of JAK3 inhibitors (4g–4j) that potently inhibited IFNγ production in an IL2-induced whole blood assay and displayed high functional selectivity for JAK3–JAK1 pathway relative to JAK2. Further modifications led to the discovery of an orally bioavailable (2-fluoro-2-methylcyclopentyl)amino analogue 5g which is a nanomolar inhibitor of both JAK3 and TYK2, functionally selective for the JAK3–JAK1 pathway versus JAK2, and active in a human whole blood assay. |
| |
| Keywords: | JAK inhibitor Pyrrolo[1 2-b]pyridazine Janus kinase JAK3 TYK2 |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
